May 18th 2024
During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL
December 14th 2022During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.
Read More
Roundtable Discussion: Ayyappan Breaks Down New and Emerging Approaches in DLBCL
November 13th 2022During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.
Read More
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Roundtable Discussion: Modi Examines Key Considerations for Third-Line Therapies in R/R DLBCL
July 28th 2022During a Targeted Oncology case-based roundtable event, Dipenkumar Modi, MD, and participants discussed the leading later-line therapy options for patients with diffuse large B-cell lymphoma.
Read More